(Q40392050)

20 September 2017

1 reference

title

The management of renal cell carcinoma (English)

1 reference

20 September 2017

K. Pittman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7521169

14 May 2024

P. Selby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7521169

14 May 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7521169

14 May 2024

publication date

1 June 1994

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:1040842894900701?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

https://api.elsevier.com/content/article/PII:1040842894900701?httpAccept=text/plain

14 May 2024

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Critical Reviews in Oncology Hematology

14 May 2024

published in

1 reference

20 September 2017

16

1 reference

20 September 2017

3

1 reference

20 September 2017

181-200

1 reference

Kidney cancer among leather workers

20 September 2017

5

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Asbestos and renal adenocarcinoma: a case-control study

14 May 2024

6

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal carcinoma after retrograde pyelography with Thorotrast

14 May 2024

7

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal adenocarcinoma and acquired cystic disease in chronic hemodialysis patients

14 May 2024

9

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Chronic renal failure: a significant risk factor in the development of acquired renal cysts and renal cell carcinoma. Case reports and review of the literature

14 May 2024

10

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Familial renal cell carcinoma: clinical and molecular genetic aspects

14 May 2024

11

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal pathology in von Hippel-Lindau disease

14 May 2024

12

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Atypical cysts and carcinomas of the kidneys in the phacomatoses. A quantitative DNA study using static and flow cytometry

14 May 2024

13

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Hereditary Renal-Cell Carcinoma Associated with a Chromosomal Translocation

14 May 2024

14

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease

14 May 2024

15

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Specific genetic change in tumors associated with von Hippel-Lindau disease

14 May 2024

16

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Identification of the von Hippel-Lindau disease tumor suppressor gene

14 May 2024

19

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Ultrastructure of the Clear Cells in Renal Carcinomas and its Importance for the Demonstration of their Renal Origin

14 May 2024

20

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Well differentiated (grade 1) clear cell renal carcinoma

14 May 2024

24

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Organ-preserving surgery in renal cell carcinoma: tumor enucleation versus partial kidney resection

14 May 2024

25

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The natural history and clinical features of renal carcinoma

14 May 2024

26

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The results of radical nephrectomy for renal cell carcinoma

14 May 2024

29

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal cell carcinoma: long-term survival and late recurrence

14 May 2024

30

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases

14 May 2024

31

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Clinical signs in renal neoplasia. A comparison of two series of three hundred cases

14 May 2024

32

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

New growths of the kidney and ureter

14 May 2024

33

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Unrecognized renal cell carcinoma. Clinical and diagnostic aspects

14 May 2024

34

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Unrecognized renal cell carcinoma. Clinical and pathological aspects

14 May 2024

35

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

14 May 2024

Incidental renal mass

37

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal cell carcinoma: natural history and results of treatment

14 May 2024

39

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Aggressive Surgical Approach to Renal Cell Carcinoma: Review of 130 Cases

14 May 2024

40

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

14 May 2024

42

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature

14 May 2024

43

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

14 May 2024

44

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis

14 May 2024

45

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

14 May 2024

47

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

14 May 2024

48

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Validation of the tumor, nodes and metastasis classification of renal cell carcinoma.

14 May 2024

49

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal Carcinoma: Computer Analysis of 96 Patients Treated by Nephrectomy

14 May 2024

50

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Stratification of risk factors in renal cell carcinoma

14 May 2024

51

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal cell carcinoma: survival and prognostic factors

14 May 2024

52

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The case for conservative surgery for renal cell carcinoma (RCC)

14 May 2024

53

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The Value of Radiotherapy in the Treatment of Hypernephroma-a Clinical Trial

14 May 2024

54

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Proceedings: Carcinoma of the kidney

14 May 2024

55

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal cell carcinoma: the Ochsner Medical Institution experience (1945-1978)

14 May 2024

57

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Bacillus Calmette-Guerin in the Treatment of Adenocarcinoma of the Kidney

14 May 2024

58

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant

14 May 2024

59

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A critical review of immunotherapy of disseminated renal adenocarcinoma

14 May 2024

60

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Current Treatment of Metastatic Renal Cell Carcinoma With Xenogeneic Immune Ribonucleic Acid

14 May 2024

61

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

14 May 2024

62

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Human recombinant interleukin-2 as an experimental therapeutic

14 May 2024

68

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

14 May 2024

Interleukin-2 toxicity

69

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

14 May 2024

71

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

14 May 2024

72

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

14 May 2024

73

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients

14 May 2024

74

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

14 May 2024

75

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

14 May 2024

76

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma

14 May 2024

77

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

14 May 2024

78

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study

14 May 2024

79

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma

14 May 2024

80

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

14 May 2024

81

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study

14 May 2024

82

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

14 May 2024

83

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

14 May 2024

85

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

14 May 2024

89

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

14 May 2024

90

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

14 May 2024

91

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Human interferons: structure and function

14 May 2024

95

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Regulation of cell growth by interferon

14 May 2024

97

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Alpha interferon for induction of remission in hairy-cell leukemia

14 May 2024

98

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Therapy of chronic myelogenous leukemia with interferon

14 May 2024

99

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon

14 May 2024

100

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas

14 May 2024

101

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

14 May 2024

103

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Interferon Therapy in Recurrent Renal Carcinoma

14 May 2024

104

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Interferon therapy in disseminated renal cell carcinoma

14 May 2024

106

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Human lymphoblastoid interferon therapy for advanced renal cell carcinoma

14 May 2024

109

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

14 May 2024

112

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group

14 May 2024

114

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Antitumor effects of human lymphoblastoid interferon on advanced renal cell carcinoma

14 May 2024

115

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

14 May 2024

118

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma

14 May 2024

119

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma

14 May 2024

121

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma

14 May 2024

124

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

14 May 2024

125

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation

14 May 2024

126

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses

14 May 2024

128

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial

14 May 2024

129

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

14 May 2024

131

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma

14 May 2024

134

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma

14 May 2024

135

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma

14 May 2024

138

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Cyclic interferon gamma treatment of patients with metastatic renal carcinoma

14 May 2024

140

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Improved subjective tolerability of interferon by combination with prednisolone

14 May 2024

142

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Combination of interferon and prednisone in human cancer

14 May 2024

143

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Alpha and gamma interferon in the treatment of advanced renal cell carcinoma

14 May 2024

144

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma

14 May 2024

145

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma

14 May 2024

146

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses

14 May 2024

150

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer

14 May 2024

151

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma

14 May 2024

152

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

14 May 2024

153

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine

14 May 2024

156

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

14 May 2024

163

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

14 May 2024

165

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

14 May 2024

166

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

14 May 2024

173

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

14 May 2024

174

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Tumour necrosis factor in man: clinical and biological observations

14 May 2024

177

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I study of recombinant human tumor necrosis factor

14 May 2024

178

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism

14 May 2024

179

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma

14 May 2024

181

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer

14 May 2024

182

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Successful tumour immunotherapy with cimetidine in mice

14 May 2024

183

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Combination of Cimetidine with Other Drugs for Treatment of Cancer

14 May 2024

184

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen, bacterial antigen, and alloantigen

14 May 2024

185

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study

14 May 2024

188

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma

14 May 2024

189

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Phase II trial of coumarin and cimetidine in advanced renal cell carcinoma.

14 May 2024

191

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Cimetidine and coumarin therapy of renal cell carcinoma. A pilot study

14 May 2024

192

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

High-dose cimetidine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group study

14 May 2024

193

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

14 May 2024

Gene therapy for cancer

194

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Human gene therapy comes of age.

14 May 2024

195

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

14 May 2024

196

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA

14 May 2024

197

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

14 May 2024

198

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer

14 May 2024

199

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

14 May 2024

200

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines

14 May 2024

201

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

14 May 2024

202

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study

14 May 2024

204

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

A Phase II study of high dose tamoxifen in progressive, metastatic renal cell

14 May 2024

206

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma

14 May 2024

207

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump

14 May 2024

208

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Radiotherapy of Metastases from Renal Cancer

14 May 2024

210

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

The role of radiation therapy in the management of metastatic renal cell carcinoma

14 May 2024

212

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Current status of the therapy of advanced renal carcinoma

14 May 2024

214

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

CANCER of the kidney and ureter

14 May 2024

215

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

Angioinfarction plus nephrectomy for metastatic renal cell carcinoma--an update

14 May 2024

218

1 reference

https://api.crossref.org/works/10.1016/1040-8428(94)90070-1

14 May 2024

Identifiers

1 reference

20 September 2017

1 reference